Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $37.9 million.

  • Aligos Therapeutics' Total Liabilities fell 104.1% to $37.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year decrease of 104.1%. This contributed to the annual value of $99.1 million for FY2024, which is 6664.76% up from last year.
  • As of Q3 2025, Aligos Therapeutics' Total Liabilities stood at $37.9 million, which was down 104.1% from $32.8 million recorded in Q2 2025.
  • Aligos Therapeutics' 5-year Total Liabilities high stood at $99.1 million for Q4 2024, and its period low was $31.0 million during Q3 2023.
  • Moreover, its 5-year median value for Total Liabilities was $42.1 million (2022), whereas its average is $46.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 8413.0% in 2024, then crashed by 4970.49% in 2025.
  • Over the past 5 years, Aligos Therapeutics' Total Liabilities (Quarter) stood at $50.6 million in 2021, then decreased by 15.49% to $42.8 million in 2022, then soared by 38.92% to $59.4 million in 2023, then soared by 66.65% to $99.1 million in 2024, then crashed by 61.71% to $37.9 million in 2025.
  • Its last three reported values are $37.9 million in Q3 2025, $32.8 million for Q2 2025, and $34.3 million during Q1 2025.